Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for diagnosing skin lesions

a skin lesions and skin technology, applied in medical science, surgical instruments for cooling, surgery, etc., can solve the problems of not always achieving the complete excision of nonmelanoma skin cancer, difficult to remove the entire lesion,

Inactive Publication Date: 2010-07-22
MEDICIS PHARMA CORP
View PDF61 Cites 55 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention provides methods for diagnosing and treating skin lesions using small molecule immune response modifier (IRM) compounds. These methods include administering an IRM compound to a treatment area of the skin and observing the skin lesion for visualization, accentuation, or detection. The methods may also involve pretreating the skin lesion prior to an ablation procedure and visualizing subclinical skin lesions. The IRM compounds used in the methods may activate TLR4, TLR7, TLR8, or both. The technical effects of the invention include improved diagnosis and treatment of skin lesions through visualization and targeted immune response modulation."

Problems solved by technology

However, the clinically visible portion of a lesion may represent only a fraction of the total lesion, making excision of the entire lesion difficult.
Currently, even with a precise preoperative diagnosis, complete excision of nonmelanoma skin cancer is not always achieved.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Pretreatment of AK Lesions with Imiquimod

[0068]Volunteers having from four to eight clinically diagnosed AK lesions located within a 25 cm2 treatment area were enrolled in a study. The study consisted of a prestudy period, a 16-week treatment period, and an 8-week post treatment period. Enrolled participants were randomized to receive either 5% imiquimod cream (ALDARA, 3M Pharmaceuticals, St. Paul, Minn.) or placebo cream containing no biologically active ingredient.

[0069]Subjects were instructed to topically administer cream from a single-use sachet. Sachets that contained imiquimod contained 250 mg of cream. One group of subjects applied cream two days per week for sixteen weeks, with dosing days occurring a minimum of three days apart. A second group of subjects applied cream three days per week for sixteen weeks, with dosing days occurring at least two days apart.

[0070]At a pretreatment visit, a baseline AK lesion count was established for each subject. Updated AK lesion counts ...

example 2

Pretreatment of BCC Lesions with Imiquimod

[0071]Prior to surgical excision of their lesions, patients with BCC lesions are pretreated with a 5% imiquimod cream, marketed as ALDARA (3M Pharmaceuticals, St. Paul, Minn.). Topical application of the 5% imiquimod cream to the BCC lesions five to seven times a week for five to seven weeks results in significant erosion, erythema, and / or edema of the BCC lesions, thereby accentuating the margins of the lesions.

example 3

Treatment of Bowen's Lesions with Imiquimod

[0072]Prior to surgical excision of their lesions, patients with Bowen's disease are pretreated with a 5% imiquimod cream, marketed as ALDARA (3M Pharmaceuticals, St. Paul, Minn.). Topical application of the 5% imiquimod cream to the lesion two to three times a week for one to three weeks results in significant erosion, erythema, and / or edema of the lesions, thereby accentuating the margins of the lesions.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods for diagnosing skin lesions are disclosed. Generally, the method include topically administering an IRM compound to a treatment area for a period of time and in an amount effective to cause a visible change in the appearance of a skin lesion including, in some cases, causing subclinical lesions to become visible. Suitable IRM compounds include agonists of one or more TLRs.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application claims priority to U.S. Provisional Patent Application No. 60 / 454,244, filed Mar. 13, 2003.BACKGROUND OF THE INVENTION[0002]Nonmelanoma skin cancer is the most common cancer in the United States, with an estimated annual incidence of more than 1,000,000 cases. Basal cell carcinomas (BCC) account for 70 to 80% of nonmelanoma skin cancers. Squamous cell carcinoma (SCC), while representing only about 20% of nonmelanoma skin cancers, are significant because of their ability to metastasize and accounts for over 2300 deaths annually. The incidence of nonmelanoma skin cancer continues to increase. Early diagnosis can be lifesaving and it is important that physicians know what treatment modalities will be the most effective.[0003]Nonmelanoma skin cancers may be treated using various procedures that excise or kill the cancerous cells. Removal of the entire tumor is essential to prevent tumor recurrence and, in some cases, metastasi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61B19/00A61B18/02A61B17/32A61B18/18A61B5/103
CPCA61B5/0059A61B5/415A61B5/418A61B18/02A61B5/445A61B5/446A61B5/444A61P35/00A61P43/00
Inventor MILLER, RICHARD L.LEE, JAMES H.FOX, TERRANCE L.
Owner MEDICIS PHARMA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com